Evolus, Inc. (NASDAQ:EOLS - Get Free Report) insider David Moatazedi sold 6,236 shares of the company's stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $13.86, for a total value of $86,430.96. Following the sale, the insider now owns 689,614 shares in the company, valued at approximately $9,558,050.04. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
David Moatazedi also recently made the following trade(s):
- On Thursday, February 22nd, David Moatazedi sold 7,706 shares of Evolus stock. The stock was sold at an average price of $13.08, for a total value of $100,794.48.
Evolus Price Performance
NASDAQ:EOLS opened at $14.00 on Friday. The stock has a 50-day simple moving average of $13.60 and a 200-day simple moving average of $10.78. Evolus, Inc. has a 1 year low of $7.07 and a 1 year high of $15.43.
Analysts Set New Price Targets
Several research firms have recently issued reports on EOLS. HC Wainwright reaffirmed a "buy" rating and set a $27.00 price objective on shares of Evolus in a research report on Friday, March 1st. Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 price objective on shares of Evolus in a research report on Wednesday, December 20th. Finally, Barclays raised Evolus from an "equal weight" rating to an "overweight" rating and upped their price objective for the stock from $10.00 to $16.00 in a research report on Monday, January 29th.
Have You Seen Elon’s New A.I. Device? (Picture Inside)
From InvestorPlace | Ad
A strange new era for mankind is upon us...
And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day.
Elon believes A.I. is advancing so fast...
This strange new device to protect us against that A.I. threat...
Get Our Latest Report on EOLS
Institutional Trading of Evolus
A number of large investors have recently made changes to their positions in EOLS. JPMorgan Chase & Co. boosted its position in shares of Evolus by 30.4% in the 1st quarter. JPMorgan Chase & Co. now owns 22,312 shares of the company's stock valued at $251,000 after purchasing an additional 5,199 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Evolus by 1.4% in the 1st quarter. Bank of New York Mellon Corp now owns 107,026 shares of the company's stock valued at $1,202,000 after purchasing an additional 1,472 shares during the period. MetLife Investment Management LLC acquired a new stake in shares of Evolus in the 1st quarter valued at about $220,000. Metropolitan Life Insurance Co NY acquired a new stake in shares of Evolus in the 1st quarter valued at about $26,000. Finally, Panagora Asset Management Inc. acquired a new stake in shares of Evolus in the 1st quarter valued at about $555,000. 90.69% of the stock is owned by institutional investors and hedge funds.
Evolus Company Profile
(
Get Free Report)
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
